See more : Norwegian Property ASA (NPRO.OL) Income Statement Analysis – Financial Results
Complete financial analysis of HOOKIPA Pharma Inc. (HOOK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of HOOKIPA Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Chow Sang Sang Holdings International Limited (CHOWF) Income Statement Analysis – Financial Results
- PT Hexindo Adiperkasa Tbk (HEXA.JK) Income Statement Analysis – Financial Results
- Arab National Bank (1080.SR) Income Statement Analysis – Financial Results
- Turnkey Communication Services Public Company Limited (TKC.BK) Income Statement Analysis – Financial Results
- Simplex Realty Limited (SIMPLXREA.BO) Income Statement Analysis – Financial Results
HOOKIPA Pharma Inc. (HOOK)
About HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 20.13M | 14.25M | 18.45M | 19.58M | 11.94M | 7.63M | 0.00 |
| Cost of Revenue | 3.55M | 3.60M | 4.64M | 53.13M | 46.31M | 21.97M | 398.00K |
| Gross Profit | 16.58M | 10.65M | 13.81M | -33.55M | -34.37M | -14.34M | -398.00K |
| Gross Profit Ratio | 82.35% | 74.72% | 74.85% | -171.31% | -287.81% | -187.91% | 0.00% |
| Research & Development | 86.42M | 68.65M | 82.85M | 54.79M | 46.31M | 21.97M | 9.77M |
| General & Administrative | 18.63M | 18.76M | 17.27M | 18.08M | 16.72M | 6.84M | 4.39M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.63M | 18.76M | 17.27M | 18.08M | 16.72M | 6.84M | 4.39M |
| Other Expenses | 0.00 | -392.00K | -2.84M | 3.07M | 601.00K | 133.00K | -25.00K |
| Operating Expenses | 117.82M | 87.40M | 100.12M | 72.87M | 63.03M | 23.20M | 12.09M |
| Cost & Expenses | 117.82M | 87.40M | 100.12M | 72.87M | 63.03M | 23.20M | 12.09M |
| Interest Income | 5.29M | 8.24M | 27.00K | 9.20M | 1.59M | 0.00 | 0.00 |
| Interest Expense | 317.00K | 687.00K | 898.00K | 786.00K | 877.00K | 778.00K | 606.00K |
| Depreciation & Amortization | 3.55M | 3.60M | 4.64M | 4.15M | 3.07M | 640.00K | 398.00K |
| EBITDA | -77.34M | -60.40M | -70.13M | -39.15M | -39.09M | -14.80M | -13.76M |
| EBITDA Ratio | -384.24% | -513.40% | -442.73% | -272.08% | -427.78% | -193.93% | 0.00% |
| Operating Income | -97.69M | -73.16M | -81.67M | -53.29M | -51.09M | -21.18M | -14.16M |
| Operating Income Ratio | -485.34% | -513.40% | -442.73% | -272.08% | -427.78% | -277.62% | 0.00% |
| Total Other Income/Expenses | 16.48M | 8.47M | 6.01M | 9.20M | 8.05M | 4.97M | 1.44M |
| Income Before Tax | -81.21M | -64.92M | -75.67M | -44.08M | -43.04M | -16.21M | -12.72M |
| Income Before Tax Ratio | -403.46% | -455.58% | -410.15% | -225.09% | -360.38% | -212.52% | 0.00% |
| Income Tax Expense | 368.00K | 230.00K | 1.00K | -10.28M | -8.89M | 24.00K | 4.00K |
| Net Income | -81.58M | -64.92M | -75.67M | -44.08M | -43.04M | -16.24M | -12.72M |
| Net Income Ratio | -405.29% | -455.58% | -410.15% | -225.09% | -360.38% | -212.83% | 0.00% |
| EPS | -8.63 | -9.90 | -23.00 | -16.90 | -2.41 | -0.99 | -0.78 |
| EPS Diluted | -8.63 | -9.90 | -23.00 | -16.90 | -2.41 | -0.99 | -0.78 |
| Weighted Avg Shares Out | 9.45M | 6.56M | 3.29M | 2.61M | 17.86M | 16.32M | 16.32M |
| Weighted Avg Shares Out (Dil) | 9.45M | 6.56M | 3.29M | 2.61M | 17.86M | 16.32M | 16.32M |
HOOKIPA to present new preclinical, translational, and clinical biomarker data at AACR further supporting the potential of arenaviral platform in oncology
Best Penny Stocks To Buy Right Now? 5 Short Squeeze Stocks To Watch
5 Short Squeeze Candidates To Watch: Kaival Brands Cost To Borrow Hits Record 409%, Blink Charging And Weber Grills Move Up
Best Penny Stocks To Buy? 8 Low Float Stocks To Watch Right Now
Trading Penny Stocks? Top Stock Market News for February 16th, 2022
Hookipa Pharma Stock Surges On HIV Pact With Gilead
HOOKIPA Pharma to Present at the H.C. Wainwright BioConnect Conference
HOOKIPA Pharma Inc. (HOOK) Reports Q3 Loss, Misses Revenue Estimates
Preview: HOOKIPA Pharma's Earnings
HOOKIPA Pharma to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
Source: https://incomestatements.info
Category: Stock Reports